Roy J. Sturgeon, Ph.D., Chairman of the LCS Board of Directors. Roy began his career at Lachman Consultants as Executive Vice President of the Compliance Practice. He progressed to the position of President and became a Senior Advisor and Outside Director to the Board after retirement. In his current role, he is responsible for working with […]
Daniel D. Bayston, CFA, Outside Director of the LCS Board of Directors. Before his retirement in 2021, he spent over 38 years as a corporate finance and business valuation professional assisting publicly traded and privately held corporate clients on various shareholder and strategic financial issues. These assignments included merger and acquisition analyses, fairness opinions, shareholder […]
Frances Zipp, President & CEO of Lachman Consultants who provides expert guidance to the pharmaceutical, biologic and biotechnology industries. Ms. Zipp joined Lachman after a 30-year career in the industry, where she held significant positions of responsibility for Quality and GxP Compliance, including various positions in drug development, operations, quality and regulatory affairs. Ms. Zipp […]
Frank Chow, Ph.D., Outside Director of the LCS Board of Directors. Dr. Chow has over 25 years of experience in the pharmaceutical industry, having held positions of increasing levels of responsibility, including executive-level positions in research and development for new and generic drugs, analytical chemistry, quality control/assurance, and regulatory compliance. During his tenure at Lachman […]
Leon Lachman, Ph.D., Outside Director and Chairman Emeritus of the LCS Board of Directors; and founder of Lachman Consultants. During his more than 40 years’ experience in the pharmaceutical industry, he has been at the forefront in the shift from the trial and error approach of dosage form development to the scientific approach to dosage […]
Robert Pollock, M.S., Outside Director of the LCS Board of Directors. He joined Lachman Consultants following a distinguished career with the FDA and the Public Health Service. His FDA experience, culminating as the Acting Deputy Director of the Office of Generic Drugs, enables him to provide expert advice and assistance on all aspects of FDA […]
David Petshaft, Esq., Chief Legal and Financial Officer of Lachman Consultants, and in this position oversees and manages the legal and financial affairs and activities of the firm. He also serves on the Board of Directors as the Treasurer/Secretary of the firm. His responsibilities include direct oversight and management of corporate activities relating to the […]
Steve Singer, Outside Director of the LCS Board of Directors, has more than four decades of experience as a corporate attorney, representing clients in a wide range of transactions. He advised numerous public and private companies in the life sciences industry, focusing on joint ventures and strategic alliances, corporate and securities law, governance matters, public […]
Linda Evans O’Connor, M.B.A., As Vice President at Lachman Consultants, Linda Evans O’Connor oversees and manages critical operational activities that include project oversight/management, work planning and workflow analysis, and quality assurance. Ms. O’Connor has a deep understanding of the pharmaceutical industry and delivers thought leadership on client projects. She maintains current industry / leading practices […]
John McShane, M.B.A., Principal Consultant, Cell & Gene Therapy, Compliance and Business Development at Lachman Consultants. An accomplished professional, Mr. McShane has extensive industry experience in international biopharmaceuticals, cell and gene therapy, and biotechnology. His distinguished career spans traditional pharmaceutical modalities and various ATMPs with a particular focus on cell and gene therapies. Mr. McShane […]
